InspireMD (NSPR) Q4 2025 earnings review
U.S. Commercial Execution Gains Traction, But Cash Burn Remains the Elephant in the Room
InspireMD's Q4 results provide the first real proof-of-concept for its U.S. commercial launch strategy. Total revenue accelerated 62% YoY to $3.1M, driven heavily by $0.9M in U.S. CGuard Prime sales, which grew 74% sequentially. More importantly, the favorable U.S. pricing dynamic reversed earlier margin compression, rocketing gross margins to 37.5% from a trough of 17.6% just two quarters ago. However, the cost of this growth is steep: operating expenses remain entrenched above $13M per quarter. While FY26 guidance projects robust 45-65% revenue growth to $13-15M, the company is still burning roughly $11-12M per quarter, meaning the race to scale revenues before the cash runway tightens is far from over.
🐂 Bull Case
The transition to a direct U.S. sales model is structurally improving profitability. With U.S. revenue growing 74% QoQ to $0.9M, gross margins have structurally shifted from the low-20% range into the high-30% range, validating management's claims about premium U.S. pricing.
The completion of enrollment for the CGUARDIANS II pivotal trial and submission of a PMA-S for TCAR indications represent critical milestones. Approval here could double the addressable U.S. market, unlocking a 30,000+ annual procedure TAM currently dominated by competitors.
🐻 Bear Case
Despite strong percentage growth in revenue, Q4 Operating Expenses ($13.3M) dwarfed Total Revenue ($3.1M). The company is still spending more than $4 for every $1 of revenue it brings in, making near-term profitability mathematically impossible.
The company's fully integrated SwitchGuard TCAR system timeline has previously slipped to 2027. Near-term TCAR growth will require physicians to pair CGuard Prime with competitor neuroprotection systems, introducing friction into the sales process.
⚖️ Verdict: ⚪
Neutral. The commercial traction and gross margin acceleration are exactly what bulls wanted to see. However, an $11.8M quarterly net loss against $3.1M in revenue highlights the steep hill InspireMD still has to climb to reach sustainable cash flow. Execution in FY26 must be flawless.
Key Themes
Accelerating U.S. Revenue Engine
In its second full quarter post-launch, U.S. sales of CGuard Prime accelerated significantly, hitting $0.9M (+74% QoQ vs $0.5M in Q3). With over 500 cumulative procedures completed across leading hospitals and IDNs, the direct commercial team is successfully navigating Value Analysis Committees (VACs).
Gross Margin Reversal Driven by Mix
A central thesis for InspireMD was that high U.S. ASPs would lift consolidated margins. This is now demonstrably true. After languishing at 17.6% in 25Q2, gross margin surged to 34.2% in 25Q3 and expanded further to 37.5% in 25Q4. As U.S. sales grow as a percentage of the total, this upward trajectory should remain stable or accelerate.
Deep Operating Losses Persist
While management celebrates revenue growth, the cost structure is concerning. Q4 OpEx was $13.3M, an increase of $3.5M YoY. While down slightly from Q3's $13.9M, it confirms that the baseline cost of supporting the U.S. launch is extremely high. The narrative of 'improving margins' rings hollow when operating margin remains deeply negative (loss from operations was $12.1M on $3.1M in sales).
TCAR Pipeline Reaches the FDA
The submission of a PMA-S to the FDA for CGuard Prime in TransCarotid Artery Revascularization (TCAR) procedures is a critical development. Currently, CGuard is approved for Transfemoral (CAS) approaches. The TCAR market represents over 30,000 annual procedures in the U.S. Opening this indication is vital to reaching the FY26 guidance targets.
Macro Shift to Endovascular-First Standard
The company continues to benefit from a structural macro shift away from open carotid endarterectomy (surgery) toward less invasive stenting, accelerated by a recent CMS reimbursement policy expansion. Stent-based procedures now account for over 40% of the U.S. market, creating a growing TAM for CGuard's proprietary MicroNet mesh technology.
Cash Runway and Future Milestone Tranches
The company ended FY25 with $54.2M in cash and marketable securities. While a vast improvement from FY24 ($34.6M), the 2025 cash burn from operations was roughly $48M. If OpEx remains flat, InspireMD has roughly 4 to 5 quarters of runway before it must rely on future financing, including the milestone-based warrant tranches tied to four quarters of U.S. sales.
Other KPIs
Stable. Grew 17% YoY. While U.S. growth dominates the narrative, the international base business has recovered from inventory management headwinds seen in H1 2025 and provides a reliable, albeit lower-margin, foundational revenue stream.
Decelerating profitability on an absolute basis. Widened substantially from a net loss of $32.0M in FY24. This $16.8M expansion in annual net loss is directly attributable to the $17.3M YoY increase in total operating expenses required to build the U.S. commercial footprint.
Guidance
Accelerating. The midpoint of $14.0M implies roughly 56% YoY growth over FY25's $9.0M. This requires the U.S. commercial team to aggressively ramp account utilization beyond initial stocking orders. If the international business holds steady at ~$9M annualized, this guidance implicitly assumes $4M to $6M in U.S. revenue for FY26.
Key Questions
U.S. Rep Productivity
With the U.S. headcount expanding aggressively throughout 2025, what are the current rep productivity metrics? How many cases per month is a tenured rep generating compared to a newly onboarded rep?
Path to Operating Leverage
Given the FY26 revenue guidance of $13M-$15M, and quarterly operating expenses currently running at ~$13M, do you expect OpEx to remain relatively flat in FY26 to allow revenue to catch up, or will you need to continue scaling expenses proportionately?
TCAR PMA-S Timeline
Now that the PMA-S for the TCAR indication is submitted, what is the expected FDA review timeline, and is any revenue from the TCAR indication factored into the $13-$15M FY26 guidance range?